Transcatheter Aortic Valve Replacement (TAVR) Clinical Trials

Clinical trials related to Transcatheter Aortic Valve Replacement (TAVR) Procedure

A Prospective, Randomized, Multicenter, Single-blind Trial to Assess the Safety and Effectiveness of the Encompass F2 Cerebral Protection Catheter Vs. Unprotected Transfemoral Transcatheter Aortic Valve Replacement

Status: Recruiting
Location: See all (10) locations...
Intervention Type: Procedure, Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The objective of this pivotal study is to compare the safety and effectiveness of the F2 CPC (Treatment group) to a Control group (no embolic protection) in participants undergoing transfemoral (TF) TAVR with commercially available devices.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 21
Maximum Age: 90
Healthy Volunteers: f
View:

• Age ≥ 21 and ≤ 90 years

• Patient meets the established criteria and indications for commercially available TAVR (e.g., balloon expandable SAPIEN valve platform, self-expanding CoreValve platform, or Navitor TAVI System) via transfemoral access and is scheduled to undergo TAVR per their treating physician.

• Patient is willing and able to comply with protocol-specified follow-up evaluations.

• Patient is able and willing to provide written informed consent

Locations
United States
Florida
NCH Baker Hospital-Naples Heart Institute
NOT_YET_RECRUITING
Naples
Indiana
St. Vincent Hospital
RECRUITING
Indianapolis
Michigan
Henry Ford Hospital
RECRUITING
Detroit
Missouri
St. Lukes Hospital Of Kansas City
RECRUITING
Kansas City
New York
Cumc/Nyph
RECRUITING
New York
Ohio
Cleveland Clinic Foundation
RECRUITING
Cleveland
Ohio Health Research Institute (aka Riverside Methodist Hospital)
NOT_YET_RECRUITING
Columbus
Virginia
University of Virginia Medical Center
NOT_YET_RECRUITING
Charlottesville
Other Locations
Australia
Monash Health Public
RECRUITING
Clayton
St Andrews War Memorial Hospital
NOT_YET_RECRUITING
Spring Hill
Contact Information
Primary
Sandra Show
sshow@encompassf2.com
7142928652
Time Frame
Start Date: 2025-09-09
Estimated Completion Date: 2027-01
Participants
Target number of participants: 500
Treatments
Experimental: F2 Filter and Delivery System
The F2 Cerebral Embolic Protection System will be used during your Transcatheter Aortic Valve Replacement procedure.
Active_comparator: No embolic protection device
No embolic protection device will be used during your Transcatheter Aortic Valve Replacement procedure.
Sponsors
Leads: EnCompass Technologies, Inc.
Collaborators: DP Clinical, Inc.

This content was sourced from clinicaltrials.gov